Abstract:Objectives Background: Catecholaminergic polymorphic ventricular tachycardia (CPVT), a malignant inherited arrhythmias, is characterised by stress-induced bidirectional or polymorphic ventricular tachycardia in absence of structural cardiac abnormalities. Unexplained syncope or sudden death in young individuals may be ascribed to CPVT. Mutations of RyR2 gene were proved to cause autosomal dominant CPVT, while mutations of CASQ2 gene cause rare autosomal recessive CPVT. To date, 155 RyR2 mutations have been reported to cause CPVT, but no mutation is identified in mainland of China. We intend to study the variants and prevalence of RyR2 gene mutations in the Chinese CPVT patients. Methods The clinical characteristics of three CPVT families provided by the National Channellopathy Registry Study were investigated, including family and personal medical histories, 12-lead electrocardiography and 24-h ambulatory electrocardiography. DNA samples of the probands and their parents were extracted from serum leukocyte. 45 exons where the known mutation clusters located were first identified by direct DNA-sequencing of PCR-amplified DNA fragment. The primers used for PCR were designed with Primer3 or Oligo6 software. The remaining 60 exons would be identified if those results were negative. Results A novel heterozygous mutation was found in exon 8 at the 506th nucleotide (506G>A) on RyR2 in a 9-year old Chinese female child. This substitution resulted in an amino acid change from arginin to glutamin at the 169th position (R169Q). This mutation was absent in her parents and 50 control subjects (100 alleles) indicating that there is a de novo mutation occurred on the proband only. The first syncope occurred with bidirectional and polymorphic ventricular tachycardia recorded at the age of seven. A heart rate of 84 beats per minute and a QTc of 349 ms with right bundle branch block were observed. Despite the use of full-dose beta-blockade (metoprolol), stress-induced syncope re-occurred once a year during the following three years. Although radiofrequency current ablation was performed successfully at the age of eight, an unexpected sudden death still occurred at the age of 10. Exon 8 where R169 resides encodes thirty seven amino acids of the RyR2 N-terminal which are highly conserved among many species. Conclusions R169Q has been reported first in an 18-year-old Taiwanese woman by Hsueh in 2006. The present study identified R169Q on RyR2 gene again in a CPVT patient of China Mainland suggesting that this position might be a mutation hotspot in Chinese CPVT patients. The study laid foundation for further deepened study and specific management of this disease.

[Clinical Features of Six Patients with Catecholaminergic Polymorphic Ventricular Tachycardia].

Characterization of a Novel Mutation in the Cardiac Ryanodine Receptor That Results in Catecholaminergic Polymorphic Ventricular Tachycardia

Clinical and genetic profiles of chinese pediatric patients with catecholaminergic polymorphic ventricular tachycardia

Clinical Characteristics, Diagnostic Evaluation and Therapeutic Strategies

The Clinical and Genetic Spectrum of Catecholaminergic Polymorphic Ventricular Tachycardia: Findings from an International Multicentre Registry

A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child.

GW27-e0966 Treatment evaluation by exercise-stress tests of catecholaminergic polymorphic ventricular tachycardia

Genetic and clinical characteristics of catecholaminergic polymorphic ventricular tachycardia in a Taiwanese nationwide cohort

Precision Medicine in Catecholaminergic Polymorphic Ventricular Tachycardia: Recent Advances Toward Personalized Care

[Catecholaminergic polymorphic ventricular tachycardia (CPVT): an insidious disease that can often lead to sudden cardiac death in young people]

Clinical Characteristics, Genetic Basis and Healthcare Resource Utilisation and Costs in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia: A Retrospective Cohort Study

MULTIPLE GENETIC VARIANTS IN CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA: A CLINICAL AND MOLECULAR REPORT FROM THE PACES CPVT REGISTRY

Clinical and Genetic Characteristics of Catecholaminergic Polymorphic Ventricular Tachycardia Combined with Left Ventricular Non-Compaction.

Management of Catecholaminergic Polymorphic Ventricular Tachycardia

Impaired Binding to Junctophilin2 and Nanostructural Alteration in CPVT Mutation

A Hotspot Mutation Ryr2-R169q for Chinese Patients with Catecholaminergic Polymorphic Ventricular Tachycardia

Serotonin and Catecholaminergic Polymorphic Ventricular Tachycardia: a Possible Therapeutic Role for SSRIs?

Arrhythmogenesis in a catecholaminergic polymorphic ventricular tachycardia mutation that depresses ryanodine receptor function

Clinical characteristics of 4 cases of polymorphic ventricular tachycardia/ventricular fibrillation initiated by idiopathic premature ventricualr contraction originating from right ventricular outflow tract

Linking the Heart and the Brain: Neurodevelopmental Disorders in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia

Description of a novel RyR2 mutation in a juvenile patient with symptomatic catecholaminergic polymorphic ventricular tachycardia in sleep and during exercise: a case report